Ypsomed Holding AG is a global medical technology company specializing in the development and manufacturing of injection and infusion systems for self-medication. The company's business model centers on business-to-business (B2B) partnerships with pharmaceutical and biotechnology companies, providing them with customized and off-the-shelf drug delivery devices for their liquid medications.
Historically operating through multiple segments, Ypsomed strategically divested its Diabetes Care division in April 2025 to become a pure-play provider of delivery systems. Today, its core Ypsomed Delivery Systems segment accounts for the vast majority of its revenue, having generated approximately 67% of its CHF 748.87 million total revenue in FY 2024/25 prior to the divestment. The product portfolio includes pen injectors, autoinjectors, and wearable large-volume injectors, which are critical for the administration of therapies such as insulin, biosimilars, and GLP-1 treatments. The company also integrates digital health solutions and connected devices to help patients track their treatments and improve adherence.
Geographically, Ypsomed generates the largest portion of its revenue in Europe, though it maintains a significant and growing presence globally. To meet the rising demand for self-injection devices, the company is heavily investing in expanding its manufacturing capacity. It operates production facilities in Switzerland and Germany, with new sites being developed in China and the United States to localize supply chains and support a target capacity of one billion devices annually by the end of the decade.
